Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value

Clare Stirzaker; Elena Zotenko; Susan J Clark

doi:10.1080/23723556.2015.1038424

Genome-wide DNA methylation profiling in triple-negative breast cancer reveals epigenetic signatures with important clinical value

Mol Cell Oncol. 2015 May 26;3(1):e1038424. doi: 10.1080/23723556.2015.1038424. eCollection 2016 Jan.

Authors

Clare Stirzaker¹, Elena Zotenko², Susan J Clark³

Affiliations

¹ Epigenetics Research Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia; These authors equally contributed to this work.
² Epigenetics Research Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; These authors equally contributed to this work.
³ Epigenetics Research Group, Genomics and Epigenetics Division, Garvan Institute of Medical Research, Sydney, New South Wales, Australia; St Vincent's Clinical School, University of NSW, Sydney, New South Wales, Australia.

Abstract

Analysis of cancer methylomes has dramatically changed our concept of the potential of diagnostic and prognostic methylation biomarkers in disease stratification. Through whole-genome methylation capture sequencing of triple-negative breast cancers (TNBCs) we recently identified differentially methylated regions with diagnostic and prognostic value that promise to stratify TNBCs for more personalized management.

Keywords: Breast cancer; DNA methylation; DNA methylation biomarkers; prognostic biomarkers; triple-negative breast cancer.